About Linkage Biosciences
Linkage Biosciences is a Healthcare company based in San Francisco (United States) founded in 2004, and was acquired by Thermo Fisher Scientific in July 2017. IVD kits for molecular diagnostics in transplant monitoring are developed. Linkage Biosciences has raised $12.64 million across 7 funding rounds from investors including Thermo Fisher Scientific, Big Sky Partners and GHC Partners. The company has 34 employees. The company was acqui-hired. Linkage Biosciences offers products and services including LinkSeq PCR Typing Kits, LinkSeq HLA Typing Kits, LinkSeq KIR Typing Kits, and LinkSeq Wipe Test. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Kits and Reagents. Its competitors include Parse Biosciences, RareCyte and RainDance; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2004 and based in San Francisco, United States, Linkage Biosciences operates in the molecular diagnostics sector. In vitro diagnostic kits are developed by the company for transplant patients, with emphasis on donor matching and monitoring processes. The product lineup encompasses HLA typing, HPA typing, wipe testing, and KIR genotyping solutions.
- Headquarters San Francisco, United States
- Employees 34
- Stage Acquired
- SectorsHealthcare
- Website linkagebio.com
- Social LinkedIn X
- Acquired by Thermo Fisher Scientific (Jul 2017)
- Total Equity Funding$12.64M (USD)
in 7 rounds
- Latest Funding Round$2M (USD), Series B
May 2013
- InvestorsThermo Fisher Scientific
& 4 more
- Employee Count34
- Acquired byThermo Fisher Scientific
(Jul 2017)
Products & Services of Linkage Biosciences
Linkage Biosciences offers a comprehensive portfolio of products and services, including LinkSeq PCR Typing Kits, LinkSeq HLA Typing Kits, LinkSeq KIR Typing Kits, and LinkSeq Wipe Test.
Rapid PCR kits for contamination-free genotyping in labs.
Kits for low resolution typing of HLA loci.
Tools for typing KIR genes and pseudogenes.
Test for detecting DNA contamination in labs.
Funding Insights of Linkage Biosciences
Linkage Biosciences has successfully raised a total of $12.64M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $2 million completed in May 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.64M
- Total Rounds 7
- Last Round Series B — $2M
- First Round $1M
(Oct 2007)
- Investors Count 4
All 7 funding rounds of Linkage Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2013 | $2M | Series B | – | – | |
| Oct 2012 | $1.55M | Series B | – | – | |
| Feb 2012 | $1.95M | Series B | – | Greenhouse Capital Partners | – |
| Sep 2011 | $2.1M | Series B | – | Fisher Capital, Greenhouse Capital Partners | |
| Apr 2010 | $2.04M | Series A | – | – | – |
| Feb 2009 | $2M | Series A | – | Greenhouse Capital Partners, James R. Fisher | |
| Oct 2007 | $1M | Seed | – | – |
5 investors in total: 4 institutional and 1 angel.
Investors in Linkage Biosciences
Linkage Biosciences has secured backing from 5 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include Thermo Fisher Scientific, Big Sky Partners and GHC Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Growth equity capital is provided by GHC Partners for industrial innovation. | greenhousecap.com | Sausalito, United States | ||
Fisher Capital is engaged in private equity and real estate investments. | fisher-capital.com | Englewood, USA | ||
Early-stage investments in US tech and energy firms are targeted. | 1999 | bigskyvc.com | Sausalito, United States | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | thermofisher.com | Waltham, United States | |
JR James R. Fisher | unknown_68bcf9ea087f48bda |
Investor details for Linkage Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Linkage Biosciences
4 dated milestones of Linkage Biosciences across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Linkage Biosciences is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Series B, of $2.0M.
- Exit Acquired by Thermo Fisher Scientific.
Competitors of Linkage Biosciences
Linkage Biosciences has 3 listed competitors in our database, 3 of them funded. They include Parse Biosciences, RareCyte and RainDance.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| parsebiosciences.com | 2018 | Seattle, United States | $100.26M | RNA-sequencing transcriptome kits for health data analysis are developed. | ||
| rarecyte.com | 2009 | Seattle, United States | $114.33M | 54 | Developer of technologies for the analysis of rare and single cells in the blood | |
| raindancetech.com | 2004 | Billerica, United States | $111.66M | 105 | Developer of nucleic acid detection and quantification systems |
Detailed competitors of Linkage Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Linkage Biosciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Linkage Biosciences
Complete news archive for Linkage Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Linkage Biosciences
Linkage Biosciences was founded in 2004 and raised its 1st funding round 3 years after it was founded.
Linkage Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Linkage Biosciences is a funded company, having raised a total of $12.64M across 7 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Oct 2007.
Linkage Biosciences has 34 employees.
Founded in 2004 and based in San Francisco, United States, Linkage Biosciences operates in the molecular diagnostics sector. In vitro diagnostic kits are developed by the company for transplant patients, with emphasis on donor matching and monitoring processes. The product lineup encompasses HLA typing, HPA typing, wipe testing, and KIR genotyping solutions.
Linkage Biosciences's top competitors include Parse Biosciences, RareCyte and RainDance.
Linkage Biosciences offers LinkSeq PCR Typing Kits, LinkSeq HLA Typing Kits, LinkSeq KIR Typing Kits, and LinkSeq Wipe Test.
Linkage Biosciences has 5 investors. Key investors include Thermo Fisher Scientific, Big Sky Partners, GHC Partners, Fisher Capital, and James R. Fisher.
Yes. Linkage Biosciences was acquired by Thermo Fisher Scientific in July 2017.